BiomEdit
PrivateLast Round
Grant
Oct 24, 2025
Total Funding Raised
$103.6M
Company Overview
BiomEdit operates in Healthcare & Life Sciences and is based in Indianapolis, Indiana. Its latest recorded funding round was a Grant round in October 2025.
BiomEdit is a biotechnology company that develops a microbiome innovation platform to discover and create products that enhance animal protein production and improve livestock disease monitoring through microbiome-derived bioactive and engineered microbial medicines.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Environmental Monitoring
Business Model
B2B
Customer Profile
Services & Consulting, Hardware Sales, Government Contracts
AI Layer
Foundation
Historical Pricing
Historical view of private secondary pricing and transaction trends.
BiomEdit Comparables
Compare BiomEdit with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Hoofprint Biome | 83% | |
| ArkeaBio | 81% | |
| Native Microbials | 80% |
For institutional investors. Book with your work email.
BiomEdit Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Oct 24, 2025 | ||||
| Grant | Jul 16, 2025 | ||||
| Series B | Jul 15, 2025 | ||||
| Grant | Nov 1, 2023 | ||||
| Series A | Feb 18, 2023 | ||||
Series A | Apr 11, 2022 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
BiomEdit Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Elevate Ventures | Series B |
| NIH RADx | Grant |
| Anterra Capital | Series A, Series B |
| Bezos Earth Fund | Grant |
| The Bill & Melinda Gates Foundation Trust | Grant |
| Viking Global Investors | Series A |
| Global Methane Hub | Grant |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 23, 2025
Secured $2M in grant funding.
- Jul 16, 2025
$1.7M grant from Global Methane Hub, NIH RADx, and USDA.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingAug 26, 2026
In Indiana, BiomEdit, Inc. is developing a new class of bio-based therapeutics to treat various animal diseases, with two products in its pipeline for launch in 2027 following its acquisition of Folium Science.
- is_developingAug 26, 2026
BiomEdit, Inc. develops genetically engineered bacterial biologics using fermentation and gene-editing to treat animal diseases in Indiana, with two products in its pipeline for 2027 launch following its acquisition of Folium Science.
- invests_into_assetsAug 25, 2026
On Aug 25th '26, BiomEdit, Inc. acquires Folium Science's technology platform and pipeline assets in Indiana, including BiomElix(R) One and Guided Biotics(R) CRISPR-Cas technology, to expand its Programmable Veterinary Biologics capabilities.
For institutional investors. Book with your work email.
BiomEdit Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about BiomEdit's valuation, stock price, and market status.
Is BiomEdit a public or private company?
BiomEdit is a private company.
What is the current stock price of BiomEdit?
BiomEdit is a private company, so its shares have no public market price. Caplight tracks BiomEdit's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is BiomEdit worth (valuation)?
Valuation information for BiomEdit is not publicly available.
Can I buy BiomEdit stock?
BiomEdit shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was BiomEdit's last funding round?
BiomEdit's most recent funding round was Grant on October 24, 2025.
Who are the main investors in BiomEdit?
Key investors in BiomEdit include Anterra Capital, Viking Global Investors.
Will BiomEdit IPO soon?
No public IPO plans have been announced for BiomEdit.
How can I track BiomEdit secondary market activity?
Caplight tracks bids, offers, and trades in BiomEdit's shares on secondary markets.